Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on Jun 13, 2023 5:01pm
114 Views
Post# 35494630

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Very encouraging, but approval will take time

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Very encouraging, but approval will take timeIt sounded somewhat along these lines from putting together a few of the answers they provided. I am sure there is way more science and nuance to understand it all and as that simple-minded layman, one  question I would have is how long is the process for sort1 to internalize, cleave the linker inside cell, and re-externalize to surface of that cell?

This has been the slide they've used for over a year now.  If it's seconds and not minutes or hours it would make a difference. If it recycles quicker than degradation, that would be helpful.  I guess the rate of docetaxol being "hoovered" up and out by the kidneys would also be worth knowing as I assume not all docetaxol lands in a spot creating TSAEs and some just exits. 

One last point on totally different topic that I recall hearing 3 times from Dr. Meric's mouth -- having a tubulin fighting drug for this stage of cancer appears to be both novel and would make it very commercial.  
<< Previous
Bullboard Posts
Next >>